PROCHLORPERAZINE EDISYLATE

Post-LOE

prochlorperazine edisylate

Pfizer

ANDAINJECTIONINJECTABLE

Approved

Jul 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

PROCHLORPERAZINE EDISYLATE (prochlorperazine edisylate) by Pfizer is clinical pharmacology prochlorperazine is a propylpiperazine derivative of phenothiazine. Approved for schizophrenia. First approved in 2022.

Drug data last refreshed 19h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Prochlorperazine is a propylpiperazine derivative of phenothiazine. Like other phenothiazines, it exerts an antiemetic effect through a depressant action on the chemoreceptor trigger zone. It also has a clinically useful antipsychotic effect. Following intramuscular…

Indications (1)

schizophrenia

Company

Worked on PROCHLORPERAZINE EDISYLATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.